GlassScriptPhysician profile
Mallorie Skinner
NPI 1154920239
$3,651.50
in general payments reported to CMS, 2019-2025
37 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $848 · 2023: $697 · 2024: $730 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.05 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $494.06 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $350.81 | 2022-2025 | |
| Philips North America LLC | $243.36 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy, (8874) Incourage |
| Grifols USA, LLC | $224.23 | 2021-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $153.06 | 2021-2024 | Opsumit, Uptravi |
| Electromed, INC. | $125.41 | 2022-2025 | Smartvest |
| Novo Nordisk INC | $114.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Ucb, INC. | $113.84 | 2025 | Bimzelx |
| Takeda Pharmaceuticals U.S.A., INC. | $112.61 | 2023-2025 | Glassia |
| Exact Sciences Corporation | $84.88 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Biotech, INC. | $81.24 | 2022-2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $76.00 | 2024-2025 | Breztri, Farxiga |
| Mylan Specialty L.P. | $73.32 | 2022-2024 | Yupelri |
| Harmony Biosciences LLC | $62.46 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $51.08 | 2022-2024 | Quviviq |
| Pulmonx Corporation | $50.25 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Lilly USA, LLC | $48.39 | 2023-2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $47.73 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $40.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.64 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Viatris Specialty LLC | $25.00 | 2025 | Yupelri |
| Merz North America, INC. | $23.57 | 2022 | |
| Genzyme Corporation | $22.81 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.04 | 2025 | Caplyta |
| Tactile Systems Technology INC | $21.25 | 2023 | Flexitouch Plus, Entre Plus |
| Vertex Pharmaceuticals Incorporated | $20.87 | 2025 | |
| Verona Pharma, INC. | $20.26 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $19.58 | 2021 | |
| Biogen, INC. | $17.08 | 2021 | |
| Leo Pharma INC. | $16.46 | 2024 | Adbry |
| Pfizer INC. | $16.08 | 2023 | |
| Jazz Pharmaceuticals INC. | $15.98 | 2021 | |
| Horizon Therapeutics Plc | $15.54 | 2022 | |
| Covis Pharma Gmbh | $13.23 | 2022 | |
| Phadia US INC. | $13.09 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallorie Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.